• About us
• Contact

Advertisement

Document › Details

Cellectis S.A.. (4/12/17). "Press Release: Cellectis S.A. to Explore Possible Initial Public Offering of Calyxt, Inc.".

	Organisation	Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)
	Group	Cellectis (Group)
	Organisation 2	Calyxt Inc. (Nasdaq Global Market: CLXT)
	Group	Cellectis (Group)
	Product	TALEN® technology (Transcription Activator-Like Effector Nuclease)
	Product 2	plant biotechnology
	Person	Moore, Jennifer (Cellectis 201511 VP Communications)
	Person 2	Harnest, Simon (Metagenomi 202107– Chief Investment Officer + SVP Strategy before Cellectis + Trout Group)

Cellectis (Alternext: ALCLS; Nasdaq: CLLS) today announces that it is exploring the possibility of an initial public offering (IPO) of a minority interest in its plant sciences business, Calyxt, Inc. No decisions have been taken at this point on the structure or timing of any IPO, and no assurance can be given that an IPO will be pursued.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.


This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.


For further information, please contact:

Media contacts:
Jennifer Moore, VP of Communications, 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241,
ckasunich@kcsa.com

IR contact:
Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008,
simon.harnest@cellectis.com

Record changed: 2023-06-05

Advertisement

More documents for Cellectis (Group)

• [1] Cellectis S.A.. (12/29/22). "Press Release: Mayflower Bioventures Launches Its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases". New York, NY....
• [2] Cellectis S.A.. (12/28/22). "Press Release: Cellectis Secures a €40 Million Credit Facility from the European Investment Bank to Support its Research, Development and Innovation Activities". Paris....
• [3] Cellectis S.A.. (2/10/22). "Press Release: Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer". New York, NY....
• [4] Metagenomi Inc.. (7/28/21). "Press Release: Metagenomi Appoints Simon Harnest as Chief Investment Officer". Emeryville, CA....
• [5] Cellectis S.A.. (2/16/21). "Press Release: Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells". Cambridge, MA & New York, NY....
• [6] Sirion Biotech GmbH. (1/7/21). "Press Release: Sirion Biotech GmbH Licensed Its LentiBoost Transduction Technology to Cellectis". Munich & Cambridge, MA....
• [7] Cellectis S.A.. (12/15/20). "Press Release: Cellectis Announces Withdrawal of Follow-On Offering". New York, NY....
• [8] Cellectis S.A.. (12/14/20). "Press Release: Cellectis Announces Launch of Follow-On Offering". New York, NY....
• [9] Cellectis S.A.. (7/6/20). "Press Release: Cellectis Reports Clinical Hold Placed on MELANI-01 Study". New York, NY....
• [10] Cellectis S.A.. (4/13/20). "Press Release: Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer". New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.